European Commission Approves CinnaGen’s Zandoriah® (teriparatide biosimilar) for Osteoporosis in Adults

Zandoriah® is CinnaGen’s first medicine to receive European Union marketing authorisation, expanding the availability of EU-authorised teriparatide biosimilars for adults with osteoporosis. | Zandoriah® becomes CinnaGen’s first EU-authorised medicine, reflecting years of investment in infrastructure and manufacturing excellence.